|
1) Koda M, Matunaga Y, Kawakami M, et al. A practical index (FibroIndex) for the prediction of significant fibrosis in patients with chronic hepatitis C. Hepatology. 2007; 45: 297-306
|
|
|
|
2) Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patients. J Hepatol. 2007; 46: 628-34
|
|
|
|
|
|
3) Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: A systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007; 102: 1-12
|
|
|
|
|
|
4) Ogawa E, Furusyo N, Toyoda K, et al. Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis. Hepatol Res. 2007; 37: 1002-10
|
|
|
|
|
|
5) Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology. 2007; 45: 1290-7
|
|
|
|
|
|
6) Foucher J, Castera L, Bernard PH, et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol. 2006; 18: 411-2
|
|
|
|
|
|
7) Terai S, Ishikawa T, Omori K, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006; 24: 2292-8
|
|
|
|
|
|
8) Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007; 46: 285-7
|
|
|
|
|
|
9) Kawaguchi K, Sakaida I, Tsuchiya M, et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun. 2004; 315: 187-95
|
|
|
|
|
|
10) Yoshiji H, Noguchi R, Ikenaka Y, et al. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Curr Med Chem. 2007; 14: 2749-54
|
|
|
|
|
|
11) Jin H, Yamamoto N, Uchida K, et al. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun. 2007; 364: 801-7
|
|
|
|
|
|
12) Yokohama S, Tokusashi Y, Nakamura K, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol. 2006; 12: 322-6
|
|
|
|
|
|
13) Sato Y, Murase K, Kato J, et al. Resolusion of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nature Biotechnology. 2008; 26: 431-42
|
|
|
|
|
|
14) Nakaya Y, Okita K, Suzuki K, et al. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition. 2007; 23: 113-20
|
|
|
|
|
|
15) Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005; 3: 705-13
|
|
|
|
|
|
16) Muto Y, Sato S, Watanabe A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res. 2006; 35: 204-14
|
|
|
|
|
17) Urata Y, Okita K, Korenaga K, et al. The effect of supplementation with branched-chain amino acids in patients with liver cirrhosis. Hepatol Res. 2007; 37: 510-6
|
|
|
|
|
|
18) Osland EJ, Powell EE, Banks M, et al. Obesity management in liver clinics: Translation of research into clinical practice. J Gastroenterol Hepatol. 2007; 22: 504-9
|
|
|
|
|
|
19) Kato J, Miyanishi K, Kobune M, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol. 2007; 42: 830-6
|
|
|
|
|
|
20) Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology. 2008; 134: 226-38
|
|
|
|
|
|
21) Theise ND, Nimmakayalu M, Gardner R, et al. Liver from bone marrow in humans. Hepatology. 2000; 32: 11-16
|
|
|
|
|
|
22) Okamoto R, Yajima T, Yamazaki M, et al. Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med. 2002; 8: 1011-7
|
|
|
|
|
|
23) Terai S, Sakaida I, Yamamoto N. An in vivo model for monitoring trans-differentiation of bone marrow cells into functional hepatocytes. J Biochem. 2003; 134: 551-8
|
|
|
|
|
|
24) Ishikawa T, Terai S, Urata Y, et al. Administration of fibroblast growth factor 2 in combination with bone marrow transplantation synergistically improves carbon-tetrachloride-induced liver fibrosis in mice. Cell Tissue Res. 2007; 327: 463-70
|
|
|
|
|
|
25) Sakaida I. Autologous bone marrow cell infusion therapy for liver cirrhosis. J Gastroenterol Hepatol. 2008; 19: 1-5
|
|
|
|
|
|
26) Furst G, Schulte am Esch J, Poll LW, et al. Portal vein embolization and autologous CD133 bone mrrow stem cells for liver regeneration: Initial experience. Radiology. 2008; 243: 171-9
|
|
|
|
|
|
27) Levicar N, Pai M, Habib NA, et al. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34＋ cells in patients with chronic liver disease. Cell Prolif. 2008; 41: 115-25
|
|
|
|
|
|
28) Yoshida H, Mamada Y, Taniai N, et al. Partial splenic embolization. Hepatol Res. 2008; 38: 225-33
|
|
|
|
|
|
29) Koconis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: A review of the English language literature. J Vasc Interv Radiol. 2007; 18: 463-81
|
|
|
|
|
|
30) Ohmoto K, Yoshioka N, Tomiyama Y, et al. Improved prognosis of cirrhosis patients with esophageal varices and thrombocytopenia treated by endoscopic variceal ligation plus partial splenic embolization. Dig Dis Sci. 2006; 51: 352-8
|
|
|
|
|
|
31) Chao CP, Nguyen H, Paz-Fumagalli R, et al. Splenic embolization in liver transplant recipients: early outcomes. Transplantation Proceedings. 2007; 39: 3194-8
|
|
|
|
|
|
32) Hiraga N, Aikata H, Takaki S, et al. The long-term outcome of patients with bleeding gastric varices after balloon-occluded retrograde transvenous obliteration. J Gastroenterol. 2007; 42: 663-72
|
|
|
|
|
|
33) 金川博史. B-RTOことはじめ. 日本門脈圧亢進症学会雑誌. 2006; 12: 151-6
|
|
|
|
|